Scholars Central

CommentaryPublished 20 Jan 2022

Analyzing bempedoic acid's effectiveness in treating hyperlipidemia clinically

Authors: Peter Smith

Annals of Experimental Biology

Volume 10 · Issue 1 · Pages 24–25

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

An innovative, first-in-class oral lipid-lowering medication is Bempedoic acid (BA). Since the end of 2020, BA has been commercialized throughout Europe as an add-on therapy for patients with high/very high cardiovascular risk who are not reaching LDL-C goals with existing lipid-lowering medications. BA has received approval from both the European Medicines Agency and the Food and Drug Administration. Italian lipid management experts recently met to discuss several unresolved issues regarding the therapeutic relevance of BA features and BA-related practical clinical issues. The panel agreed to have its thoughts collected in a ten-question format.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Annals of Experimental Biology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalAnnals of Experimental Biology
  • SubjectBiology
  • BylineArticles whose byline prints “Peter Smith”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels